Roche navify Tumor Board 2023
Improving Tumor Board Meetings with a Holistic View of Data That Facilitates Multidisciplinary Team Collaboration and Optimizes Care Decisions
Tumor board conferences play a crucial role in the comprehensive, effective management of cancer patients. These meetings involve a multidisciplinary team that collectively evaluates complex cancer cases and collaborates to make informed, personalized treatment decisions. The absence of tumor board technology can hinder effective communication, collaboration, data sharing, and decision-making, which potentially leads to delays, inaccuracies, and suboptimal care. Roche aims to solve these potential problems with navify Tumor Board. This report offers an initial look at customers’ experiences with this product.
If you don't have a login, getting started is easy.
Key Findings:
- navify Tumor Board Customer Experience: An Initial Look
- Points to Ponder
- Roche Diagnostics: Company Profile at a Glance
- Solution Technical Specifications (provided by Roche Diagnostics)
Project Manager
Kyle Chilton
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.